Floatz logo

Oric-114

EGFR-mutated NSCLC

ORIC PharmaceuticalsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the EGFR-mutated NSCLC cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Oric-114 is also rated in:

neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →